Frontlight ResearchEarly access
WithdrawnEarly phase 1
a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)
Key facts
- Who runs it
- HuidaGene Therapeutics Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 30 Mar 2023
- Ended
- 8 Apr 2025
- Type of study
- Interventional
- Treatments tested
- HG205
- Record updated
- 10 April 2025
- Why it stopped
- Huidagene stopped this program as lack of patients in China
Who can take part
- Age
- 1 year to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or females between 1 and 16 years of age at the time the subject/parent/legal guardian signs the informed consent form
- Willing to adhere to the protocol as evidenced by written informed consent or parental permission and subject assent
- Molecular diagnosis of biallelic mutations in the OTOF gene with at least one mutation being p.Q829X through collected blood samples at screening
- Based on auditory brainstem response (ABR), clinically diagnosed sensorineural hearing loss (SNHL) with the following hearing thresholds: severe (65 dB ≤ hearing threshold < 80 dB) or profound (80 dB ≤ hearing threshold < 95 dB) or complete (hearing threshold ≥ 95 dB) hearing loss in both ears
- Acceptable hematology, clinical chemistry, and urine laboratory parameters
Who cannot take part
- Presence of cochlear implants in the study ear
- Prior participation in clinical study with an investigational drug within the past six months
- Prior gene therapy treatments
- Pre-existing other hearing-loss conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints or complications of surgery
- Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter hearing function
- Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation
- Complicating systemic diseases or clinically significant abnormal baseline laboratory values
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.
The group in the trial
- HG205Treatment being tested
Method of Administration: Once Unilateral intracochlear injection/subject; The duration of the study for each subject includes a screening period, enrollment visit, treatment visit, a 26-week follow-up period, and a 5-year long-term safety follow-up after the injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Multiple-cohort, Dose-finding, Investigator-initiated Trial to Evaluate the Safety, Tolerability, and Efficacy of HG205 RNA Base-Editing Therapy in Subjects With OTOF-p.Q829X Mutation-associated Hearing Loss
- Record updated
- 10 April 2025